{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:12:38Z","timestamp":1790493158796,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.beha.2019.05.008","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T11:27:40Z","timestamp":1558697260000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Venetoclax-based therapies for acute myeloid leukemia"],"prefix":"10.1016","volume":"32","author":[{"given":"Veronica A.","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2019.05.008_bib1","series-title":"SEER cancer statistics review 1975-2007 National cancer institute SEER cancer statistics review 1975-2007","first-page":"1975","author":"Altekruse","year":"2010"},{"issue":"4","key":"10.1016\/j.beha.2019.05.008_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.05.008_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.05.008_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"17","key":"10.1016\/j.beha.2019.05.008_bib5","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib6","article-title":"Mcl-1\/CDK9 targeting by AZD5991\/AZD4573 overcomes intrinsic and acquired venetoclax resistance in vitro and in vivo in PDX model of AML through modulation of cell death and metabolic functions","volume":"132","author":"Carter","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.05.008_bib7","first-page":"104","article-title":"Mechanisms of action of Bcl-2 family proteins","volume":"5","author":"Shamas","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"10.1016\/j.beha.2019.05.008_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.molcel.2005.02.003","article-title":"BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly","volume":"17","author":"Bouchier-Hayes","year":"2005","journal-title":"Mol Cell"},{"issue":"9","key":"10.1016\/j.beha.2019.05.008_bib9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The BCL2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat Rev Canc"},{"issue":"3","key":"10.1016\/j.beha.2019.05.008_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","article-title":"BCL-2, BCL-XLsequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.beha.2019.05.008_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12457","article-title":"ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets","volume":"163","author":"Vogler","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2019.05.008_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2019.05.008_bib13","author":"U.S. Food and Drug Administration"},{"issue":"12","key":"10.1016\/j.beha.2019.05.008_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Jaeger","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2019.05.008_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid Leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2019.05.008_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2019.05.008_bib17","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.beha.2019.05.008_bib18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological correlates of response in a phase 2 study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib19","article-title":"Venetoclax with low-dose cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy","volume":"132","author":"Wei","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.05.008_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive , elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.05.008_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia\u202f: a non-randomised , open-label , phase 1b study","volume":"19","author":"Dinardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.05.008_bib22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.beha.2019.05.008_bib23","article-title":"Treatment with low-dose cytarabine in elderly patients (age 70 Years or older) with acute myeloid leukemia: a single institution experience","volume":"8","author":"Heiblig","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"21","key":"10.1016\/j.beha.2019.05.008_bib24","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2019.05.008_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30 % blasts","volume":"126","author":"Seymour","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.05.008_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.05.008_bib27","author":"U.S. Food and Drug Administration"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib28","article-title":"Response to venetoclax and hypomethylating agents among prognostic risk groups and genetic subtypes of acute myeloid leukemia","volume":"132","author":"Aldoss","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib29","article-title":"Interim analysis of phase II study of venetoclax with 10-day decitabine (DEC10-VEN) in acute myeloid leukemia and myelodysplastic syndrome","volume":"132","author":"Maiti","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib30","article-title":"Molecular patterns of response and outcome in the chemotherapy and venetoclax in elderly AML trial (CAVEAT study)","volume":"132","author":"Wei","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib31","article-title":"Venetoclax in combination with FLAG-IDA chemotherapy (FLAG-V-I) for fit, relapsed\/refractory AML patients: interim results of a phase 1b\/2 dose escalation and expansion study","volume":"132","author":"DiNardo","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.05.008_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia Venetoclax","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.05.008_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"Dinardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib34","article-title":"Retrospective analysis of adults with acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center","volume":"132","author":"Tenold","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib35","article-title":"Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies","volume":"130","author":"Goldberg","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib36","article-title":"Addition of venetoclax to patients with acute myeloid leukemia relapsing after treatment with hypomethylating agents. Multicenter historical prospective study","volume":"132","author":"Ram","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2019.05.008_bib37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.beha.2019.05.008_bib38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia Patients\u202f: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther [Internet]"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib39","article-title":"Mechanisms underlying superior efficacy of Co-targeting BET proteins and anti-apoptotic BCL2 or MCL1 protein against AML blast progenitor cells","volume":"132","author":"Mill","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib40","article-title":"Biomarkers predicting venetoclax sensitivity and strategies for venetoclax combination treatment","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2019.05.008_bib41","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML\u202f: an unexpected bonus\u202f?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2019.05.008_bib42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14251","article-title":"BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma","volume":"179","author":"Dousset","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2019.05.008_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2019.05.008_bib44","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2019.05.008_bib45","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Olejniczak","year":"2018","journal-title":"Cancer Discov"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib46","article-title":"Inhibition of XPO1 By KPT-330 (selinexor) enhances cell death induced by the Bcl-2 selective inhibitor ABT-199 (venetoclax) through downregulation of Mcl-1 in acute myeloid leukemia","volume":"130","author":"Luedtke","year":"2017","journal-title":"Blood"},{"issue":"102","key":"10.1016\/j.beha.2019.05.008_bib47","doi-asserted-by":"crossref","first-page":"37777","DOI":"10.18632\/oncotarget.26540","article-title":"Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells","volume":"9","author":"Balakrishnan","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.beha.2019.05.008_bib48","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib49","article-title":"Venetoclax synergistically enhances the Antileukemic activity of imipridone ONC213, a novel imipridone ONC201 analog, in acute myeloid leukemia","volume":"132","author":"Su","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.05.008_bib50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic Lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior Antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.beha.2019.05.008_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2019.05.008_bib52","first-page":"1158","article-title":"The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia","volume":"76","author":"Vidacs","year":"2015","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.beha.2019.05.008_bib53","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2016.65","article-title":"Genetic alterations and their clinical implications in older patients with acute myeloid leukemia","volume":"30","author":"Tsai","year":"2016","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib54","article-title":"BCL-2 inhibitor venetoclax (ABT-199) and MEK inhibitor GDC-0973 synergise to target AML progenitors and overcome drug resistance with the use of PET scanning in a mouse model of HR-MDS to monitor response to treatment","volume":"132","author":"Padua","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib55","article-title":"Preliminary results from a phase Ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R\/R) AML","volume":"130","author":"Daver","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.05.008_bib56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib57","article-title":"Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models","volume":"132","author":"Cathelin","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2019.05.008_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3735.3735","article-title":"AG-221, an oral, selective, first-in-class, potent IDH2-R140Q mutant inhibitor, induces differentiation in a Xenotransplant model","volume":"124","author":"Quivoron","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2019.05.008_bib59","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1158\/2159-8290.CD-16-1049","article-title":"Combination targeted therapy to disrupt Aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2 - and TET2 -mutant acute myeloid leukemia","volume":"7","author":"Ward","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.beha.2019.05.008_bib60","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.05.008_bib61","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Farnoud","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.05.008_bib62","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib63","article-title":"FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models","volume":"130","author":"Mali","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2019.05.008_bib64","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib65","article-title":"Upregulation of Bcl-2 confers resistance to FLT3 inhibition in FLT3-ITD AML with secondary acquired mutations","volume":"132","author":"Yamatani","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2019.05.008_bib66","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1182\/blood-2018-99-115993","article-title":"Single centre experience in treating elderly patients with acute myeloid leukaemia or high risk myelodysplastic syndrome with a combination of low dose cytarabine, venetoclax and fluconazole (VeLDAC-F)","volume":"132","author":"Child","year":"2018","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:22Z","timestamp":1761498382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619300362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1521692619300362"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.05.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax-based therapies for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}